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Letters to the EditorTargeting CD81 T cells prevents
psoriasis developmentTo the Editor:
In psoriasis, intraepidermal T cells are predominantly CD81
and represent key effector cells. Here, we show that these
T cells produce pathogenic IL-17 and that neutralization of
CD81 T cells effectively prevents psoriasis development
in vivo.
Psoriasis is a common inflammatory skin disease, resulting
from the interaction of genetic and environmental triggers,
leading to dysregulated immune response of innate and adaptive
immune cells.1,2 T lymphocytes infiltrating psoriasis skin lesions
play key effector roles by driving disease development and
maintenance. Traditionally, CD41 TH cells producing proinflam-
matory cytokines, such as IL-17A, IL-22, and IFN-g, are re-
garded as the main pathogenic T-cell subpopulation. However,
CD81 T cells, which are present in healthy skin as tissue resi-
dent memory T cells (TRM),
3 have been shown to produce a
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274abundantly present in the psoriatic epidermis and potentially
recognize peptide antigens presented on MHC class I molecules,
such as HLACw6, which is the strongest psoriasis susceptibility
allele.5 Furthermore, we have previously shown that intraepider-
mal T cells represent key effector cells in psoriasis development
and that impeding the entry of T cells into the epidermis, by
blocking a1b1-integrin, prevents the development of psoriasis
in the clinically relevant AGR mouse model of psoriasis.6
Thus, we set out to explore the pathogenic relevance of CD81
T cells in psoriasis.
We first performed a time course experiment using the AGR
mouse model. AGR mice are grafted with noninvolved skin from
patients with psoriasis, which spontaneously develops a psoriatic
phenotype after 4 to 6 weeks.6 Thus, at days 0, 7, 21, and 35, skin
transplants were harvested and processed for histological and
immunohistochemical assessment as described previously.6 In
line with earlier findings, while the proliferation of dermal
T cells preceded epidermal changes, the numerical expansion of
the epidermal T-cell pool temporally coincided with the onset
of the psoriatic phenotype, as shown by the papillomatosis indexC Ki67, day 0
Ki67, day 35
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FIG 2. Epidermal CD81 T cells are highly pathogenic and their blockade prevents the development of pso-
riasis. Relative frequency (A) and representative zebra plot (B) of CD31CD81 T cells among live CD451 cells
isolated from the epidermis and the dermis of 5 patients with psoriasis, with each patient denoted by a con-
necting line. Functional characterization of epidermal and dermal CD31CD81 T cells as IL-17A1 (C), with
representative zebra plot in (D) IL-17A1IFN-g1 and IL-17A1IL-221 (E) obtained by intracellular cytokine
staining after phorbol 12-myristate 13-acetate/ionomycin stimulation. Each line connects epidermal and
dermal CD81 T cells from the same patient. F,Microscopic changes of nonlesional psoriatic skin quantified
using the papillomatosis index 35 days after transplantation onto AGR mice treated with isotype control
mAb (mean6 SEM, 4.076 0.72), mAb to CD8 (2.176 0.22), or anti-TNFmAb (2.176 0.08).G, Representative
microscopic views of nonlesional psoriatic skin 35 days after transplantation onto AGR mice treated with
isotype control mAb, mAb to CD8, or anti-TNF mAb. B and D, Zebra plot shown is representative of 1 of
5 patients. F, Data shown represent pooled results from 2 independent experiments with skin of 2 patients.
Each symbol represents a transplanted mouse (n 5 5-7). Statistical analyses in A, C, and E were performed
by paired t test and in F with ANOVA followed by Bonferroni correction. All testing was 2-sided, and a P
value of less than .05 was considered to indicate statistical significance.
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LETTERS TO THE EDITOR 275(Fig 1,A andC, and Conrad et al6).Moreover, the accumulation of
epidermal T cells paralleled the increase in proliferating keratino-
cytes as identified by positive Ki67-staining (Fig 1, B and C).
Importantly, in the absence of T-cell expansion upon transplanta-
tion, which did not occur in one of the experiments we performed,
we did not observe any epidermal pathology, in terms of both pap-
illomatosis and frequency of proliferating keratinocytes (see Fig
E1 in this article’s Online Repository at www.jacionline.org).
Thus, the accumulation of epidermal T cells induces both kerati-
nocyte hyperproliferation and onset of papillomatosis, 2 hall-
marks of psoriasis, thereby further confirming the role of
intraepidermal T cells as key effectors in psoriasis.In keeping with the classical distribution of CD41 and CD81
T cells in human psoriatic lesions, intraepidermal T cells in
skin grafts 35 days posttransplant were predominantly CD81
T cells (see Fig E2 in this article’s Online Repository at www.
jacionline.org). Psoriatic CD81 T cells have been previously
characterized in terms of their cytokine production; however, lit-
tle distinction has beenmade between those residing in the dermis
and the epidermis in the absence of post-isolation in vitro culture.
Thus, to obtain a faithful functional characterization of psoriatic
CD81 T cells, we isolated T cells from the epidermis and the
dermis of psoriasis lesions and performed intracellular cytokine
staining and fluorescence-activated cell sorting analyses. Among
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was significantly higher in the epidermis than in the dermis
(Fig 2, A and B). Interestingly, the frequency of epidermal
CD31CD81 T cells producing IL17A (Fig 2, C and D) or
double-producing both IFN-g and IL-17A or IL-22 and IL-17A,
respectively (Fig 2, E), significantly exceeded that of dermal
CD31CD81 T cells. No significant difference was found for
IFN-g1, IL-221, or IL-221IFN-g1 T cells between the dermis
and the epidermis (see Fig E3 in this article’s Online Repository
at www.jacionline.org). Thus, the main factor differentiating the
epidermal from the dermal CD81 T-cell population is an active
Tc17 phenotype.
On the basis of these findings, we sought to determine the
in vivo pathogenic relevance of CD81 T cells infiltrating psoriasis
lesions. Therefore, we treated xenotransplanted mice with either
1 mg mAb to human CD8 (M-T807) or the corresponding isotype
control mAb on days 0 and 14, or mAb to TNF (infliximab, 1 mg
intravenously on days 7 and 21 after transplantation). Isotype con-
trol antibody-treated skin grafts developed fully fledged psoriasis
over the course of 35 days (Fig 2, F and G). Injection of mAb to
CD8 resulted in a significantly reduced papillomatosis index and
complete blockade of psoriasis development. The effect was
equivalent to that obtainedwith TNF antagonists, a current bench-
mark in psoriasis treatment (Fig 2, F and G).
CD81 T cells and their role in psoriasis are currently under the
spotlight (see Fig E4 in this article’s Online Repository at www.
jacionline.org). CD81 T cells isolated from patients with psoria-
sis produce psoriasis-relevant cytokines, they are retained in the
epidermis as TRM after successful therapy,
7 and LL-37–specific
CD81 T cells expressing a1b1-integrin, a key molecule for traf-
ficking of T cells into psoriatic epidermis,6 have been identified in
psoriatic blood.8 The preferential anatomical location in the
epidermis makes CD81 T cells ideally located to engage in a
pathogenic cross talk with keratinocytes (Fig E4); a recent mouse
model of psoriasiform murine inflammation relying on keratino-
cyte genetic abnormalities identified CD81 T cells as critical
players.9 In addition, we show that the accumulation of epidermal
T cells, which mainly reflect CD81 T cells, correlates with the
onset of keratinocyte hyperproliferation and papillomatosis, 2
characteristic features of psoriasis. Epidermal CD81 T cells
display highly pathogenic features, and the significantly increased
frequency of those producing IL-17A, alone or in combination
with IL-22 and IFN-g, makes them a reasonable primary source
for this pivotal cytokine, whose clinical targeting is proving high-
ly successful.10 Finally, we show that blockade of CD81 T cells
via a neutralizing mAb prevents the development of psoriasis in
a clinically relevant xenotransplantation mouse model, thus un-
covering a critical role for them in driving pathology. These find-
ings may provide the basis for the design of new strategies
targeting CD81 T cells for the treatment of psoriasis.
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from multiple subjects exhibit dif-
ferential responses to H3N2 influ-
enza virus infection in vitroTo the Editor:
Nasal epithelium is the first line of mechanical and immuno-
logic defense in the upper respiratory tract.1 Upper respiratory
METHODS
Animal studies were approved by the Kantonale Veterinaeramt of Zurich.
Human studies, conducted according to the Declaration of Helsinki, were
approved by the institutional review boards of the University Hospital of Zurich
and Guy’s and St Thomas’ Hospital and informed patient consents were
obtained. Xenotransplantation of noninvolved psoriatic skin, obtained from 3
patients with psoriasis, was performed as previously described using AGR129
mice, which are deficient in type I (A) and type II (G) IFN receptors in addition
to being Rag22/2 (R). After 4 to 6 weeks, these skin grafts spontaneously
develop a psoriatic phenotype including thickening of the epidermis (acantho-
sis), elongation of the rete ridges (papillomatosis), and increased numbers of
dermal and epidermal T cells, closely reflecting the pathology of patient samp-
les.E1 For fluorescence-activated cell sorting analyses of skin T cells, we ob-
tained 4-mm full-thickness skin biopsies from 5 patients with psoriasis,
incubated them in 0.5mol/LEDTAat 378C for 3 hours to separate the epidermis
and the dermis, and then digested them separately in 0.8 mg/mL collagenase
type IV in RPMI 1 10%FCS 1 1%Pen/Strep (cRPMI) at 48C overnight.
EDTA treatment does not affect the expression of cell surface markers, such
as CD4, in contrast to thewidely used dispase treatment (data not shown). Sub-
sequently, digested tissue was stimulated with phorbol 12-myristate 13-acetate
(50 ng/mL) and ionomicin (1mg/mL) in the presence of brefeldinA (3mM)and
monensin (3mM) in cRPMI at 378C for 5 hours. Dead cells were excluded from
the analysis by staining with Live Dead Yellow (Life Technologies, Carlsbad,
Calif). Cells were stained for surface markers, fixed and permeabilized, and
stained for intracellular cytokines. The following antibodies were used: anti-
CD3 APC (SK7, BD Biosciences, Franklin Lakes, NJ), anti-CD4 BV650
(SK3, BD Biosciences), anti-CD8 PE-Texas Red (3B5, Invitrogen, Carlsbad,
Calif), anti-CD45 V500 (HI30, BD Biosciences), anti–IL-17A V450 (N49-
653, BD Biosciences), anti–IL-22 PerCP-eFluor710 (22URTI, eBiosciences,
San Diego, Calif), and anti–IFN-g A700 (B27, BD Biosciences).
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FIG E1. Absence of epidermal pathology after failed T-cell expansion. Quantification of T cells present in
skin samples upon transplantation in the AGR mouse model (days 0, 7, 21, and 35): dermal (dashed black
line) and epidermal (solid black line) T-cell counts compared with papillomatosis index (solid green line,
A) and Ki-67 postive keratinocytes (solid red line, B) during psoriasis development. Microscopic view of
nonlesional psoriatic skin stained with an mAb to Ki-67 on the day of transplantation onto AGR mice and
on day 35 (C). Data in A and B reflect 1 experiment with skin from a single donor not showing any relevant
T-cell proliferation upon transplantation (n 5 2 for every time point).
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FIG E2. As in classical human psoriasis, intraepidermal T cells in the AGR mouse model represent mostly
CD81 T cells. Microscopic view of representative CD3, CD4, and CD8 immunostaining of nonlesional
psoriatic skin upon development of fully fledged psoriasis, 35 days after engraftment onto AGR mice.
Arrowheads depict intraepidermal CD81 T cells, and arrows depict dermal CD41 T cells.
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FIG E3. No differences in IL-22 and IFN-g production between epidermal
and dermal CD81 T cells. Functional characterization of epidermal and
dermal CD31 CD81 T cells isolated from the epidermis and the dermis of
5 patients with psoriasis. Percentages of IL-221, IFN-g1, and IL-221 IFN-g1
CD81 T cells, as obtained by intracellular cytokine staining upon phorbol
12-myristate 13-acetate/ionomycin stimulation, show no differences be-
tween dermal and epidermal CD81 T cells. Each line connects epidermal
and dermal CD81 T cells from the same patient.
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FIG E4. The role of CD81 T cells in psoriasis immunopathogenesis. Environmental triggers (eg, skin injury,
known as Koebner phenomenon) induce the expression of LL37 by keratinocytes, which forms complexes
with self-DNA/RNA released by dying cells. These complexes activate skin-infiltrating plasmacytoid den-
dritic cells (pDCs) to produce IFN-a, which in turn—together with LL37-RNA complexes—promotes matura-
tion and activation of conventional dendritic cells producing IL-23. This leads to expansion and activation of
autoreactive CD81 T cells, as well as CD41 T cells, in the dermis. Although CD41 T cells remain principally
within the dermis, activated CD81 T cells acquire expression of very late antigen (VLA)-1 and migrate into
the epidermis. Subsequently, potentially upon recognition of autoantigens on keratinocytes via MHC-I, in-
traepidermal CD81 T cells release IL-17, which is critically involved in psoriatic inflammation and its
pathogenesis.
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TABLE E1. Cellular and histologic changes over time during psoriasis development
Experiment depicted in Fig 1 Day 0 Day 7 Day 21 Day 35
Dermal T cells 3.22 (0.71) 16.08 (3.51) 22.30 (8.66) 6.65 (2.11)
Epidermal T cells 0.23 (0.08) 0.33 (0.24) 10.50 (1.62) 16.32 (1.68)
Papillomatosis index 1.507 (0.06) 1.598 (0.04) 2.529 (0.28) 2.978 (0.32)
Ki-67 16.67 (3.83) 11.67 (1.70) 56.39 (9.91) 72.78 (29.51)
Mean and SEM values of experimental data depicted in Fig 1, A and B. Mean (6 SEM) values of dermal and epidermal T cells, papillomatosis index, and Ki-67 positive
keratinocytes in skin samples upon xenotransplantation in the AGR mouse model at indicated time points. Values correspond to the data depicted in Fig 1, A and B.
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